U.S. Markets close in 1 hr 44 mins

Novelion Therapeutics Inc. (NVLN)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
0.68000.0000 (0.00%)
As of 9:40AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.6800
BidN/A x N/A
AskN/A x N/A
Day's Range0.6800 - 0.6800
52 Week Range0.6800 - 0.6800
Avg. VolumeN/A
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Novelion Therapeutics Announces Nasdaq Delisting

    Novelion Therapeutics Inc. (NVLN) (“Novelion” or the “Company”), announced that on October 7, 2019 the Nasdaq Office of General Counsel notified the Company that the Nasdaq Hearing Panel (the “Panel”) has determined to affirm the Listing Qualifications Staff’s (“Staff”) decision to delist the Company’s shares from the Nasdaq Stock Market LLC (“Nasdaq”) and that trading of the Company’s common shares will be suspended effective at the open of business on October 9, 2019. The Company does not intend to seek review of or appeal the Panel’s determination.

  • GlobeNewswire

    Novelion Therapeutics Announces Filing of Definitive Proxy Statement in Connection with Proposed Liquidation and Other Matters

    Novelion Therapeutics Inc. (NVLN) (“Novelion” or the “Company”) today announced that it has filed its notice of meeting and definitive proxy statement with the applicable securities regulatory authorities in connection with the proposals to be voted on at the Company’s 2019 annual general meeting of shareholders (the “Annual Meeting”), including the proposed liquidation and dissolution of the Company (the “Liquidation Proposal”).  Novelion expects to commence mailing the definitive proxy statement and information circular (the “Proxy Materials”) to shareholders on or about October 4, 2019.

  • GlobeNewswire

    Novelion Therapeutics Announces Completion of Aegerion Transaction and Departure of Certain Directors and Officers

    Novelion Therapeutics Inc. (NVLN) (“Novelion” or the “Company”), announced that, further to its press release dated September 11, 2019, the acquisition by Amryt Pharma Plc (“Amryt”) of 100% of the outstanding equity interests of Novelion’s reorganized subsidiary, Aegerion Pharmaceuticals, Inc. (“Aegerion”) as contemplated in Aegerion’s First Amended Joint Chapter 11 Plan (the “Amryt Transaction”), has been completed. On September 24, 2019, Aegerion completed the Amryt Transaction (the “Closing”). The consideration for the Amryt Transaction has been satisfied through the issuance of ordinary Amryt shares (the “Ordinary Shares”), or American depository receipts representing Ordinary Shares, to stakeholders of Aegerion.